Black Rock Inc. Xilio Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 66,418 shares of XLO stock, worth $66,418. This represents 0.0% of its overall portfolio holdings.

Number of Shares

66,418

Previous 45,355 46.44%

Holding current value

$66,418

Previous $48,000 31.25%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.9 - $1.53 $18,956 - $32,226	21,063 Added 46.44%	66,418 $63,000
Q1 2024 May 10, 2024	SELL	$0.55 - $1.08 $828 - $1,627	-1,507 Reduced 3.22%	45,355 $48,000
Q4 2023 Feb 13, 2024	SELL	$0.5 - $2.5 $261 - $1,305	-522 Reduced 1.1%	46,862 $25,000
Q3 2023 Nov 13, 2023	SELL	$2.11 - $2.9 $3,854 - $5,298	-1,827 Reduced 3.71%	47,384 $99,000
Q2 2023 Aug 11, 2023	SELL	$2.55 - $3.46 $4,574 - $6,207	-1,794 Reduced 3.52%	49,211 $128,000
Q1 2023 May 12, 2023	BUY	$2.66 - $4.28 $4,165 - $6,702	1,566 Added 3.17%	51,005 $161,000
Q4 2022 Feb 13, 2023	BUY	$1.97 - $3.03 $6,069 - $9,335	3,081 Added 6.65%	49,439 $132,000
Q3 2022 Nov 14, 2022	SELL	$2.07 - $3.44 $2,701 - $4,489	-1,305 Reduced 2.74%	46,358 $135,000
Q2 2022 Aug 12, 2022	SELL	$2.08 - $7.2 $524,353 - $1.82 Million	-252,093 Reduced 84.1%	47,663 $139,000
Q1 2022 May 12, 2022	SELL	$6.63 - $16.05 $161,360 - $390,624	-24,338 Reduced 7.51%	299,756 $2.12 Million
Q4 2021 Feb 10, 2022	BUY	$9.69 - $25.11 $3.14 Million - $8.14 Million	324,094 New	324,094 $5.18 Million

Others Institutions Holding XLO

# of Institutions

Shares Held

14M

Call Options Held

Put Options Held

View Full List

About Xilio Therapeutics, Inc.

Ticker XLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,471,600
Market Cap $27.5M
Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...

More about XLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account